Kidney cancer (renal cell carcinoma) begins in the lining of the kidney's tiny filtering tubes and is often called a “silent cancer” because early stage tumors rarely cause any noticeable symptoms—yet when detected early, cure rates are excellent.
Globally, over 430,000 new cases of kidney cancer are diagnosed each year. Because the disease silently progresses without early warning signs, many patients are already at an advanced stage when first detected. However, timely intervention can still open a window for curative outcomes — so prompt medical evaluation, especially through routine ultrasound screening, is essential.
China sees more than 78,000 new cases of kidney cancer annually — the highest number of any country in the world. At Fosun Health, this extraordinary case volume has given our expert teams a depth of experience that ensures precision in every aspect of care, from early imaging diagnosis and minimally invasive nephron sparing surgery to targeted therapy and immunotherapy.
Every kidney cancer program has surgery, targeted therapy, and immunotherapy. Here is what makes ours different:
"They found a tumor in my kidney. Do I have to lose the entire kidney? What if my other kidney fails later?"
The challenge: The kidney is not an organ you can afford to lose lightly. Chronic kidney disease, hypertension, diabetes, and aging all threaten the remaining kidney. Nephron loss accelerates renal failure, dialysis dependency, and cardiovascular risk. Yet many patients are told "we must remove the whole kidney to be safe"—even when the tumor is small and peripheral.
Our answer: Nephron-sparing management that removes the tumor while keeping every possible functioning unit:
- Robotic Partial Nephrectomy: The Da Vinci robot provides 10× magnified 3D vision and tremor-free, wristed instruments that enable "precision renal surgery." We clamp the renal artery, excise the tumor with a margin of healthy parenchyma, and reconstruct the renal defect—all while preserving >90% of functional kidney volume. Warm ischemia time is minimized to protect long-term renal function. The outcome: cancer controlled, kidney saved.
- Image-Guided Ablation: For small renal masses (typically <4 cm), especially in elderly patients, those with solitary kidneys, or those unfit for surgery, radiofrequency ablation (RFA), microwave ablation (MWA), or cryoablation destroys the tumor through a needle puncture under CT or ultrasound guidance. No large incision. No kidney removal. The tumor is ablated; the surrounding healthy nephrons remain fully functional.
- Active Surveillance with Precision: For elderly patients with very small, slow-growing renal masses, we offer structured surveillance with 3–6 monthly contrast-enhanced imaging—deferring intervention until progression, preserving quality of life.
What this means for you: A kidney tumor does not automatically mean losing the kidney. Depending on size and location, we can cut out only the tumor—or burn/freeze it through a needle—leaving the vast majority of your renal function intact.
"My tumor is enormous, and I am bleeding into my urine. I am too weak for major surgery right now. Can you stabilize me first?"
The challenge: Some renal tumors grow to massive size before detection, invading the renal vein or causing life-threatening hemorrhage. Patients present anemic, cachectic, and unstable—far too frail for immediate radical nephrectomy. Without rapid control, the downward spiral accelerates.
Our answer: Superselective renal arterial embolization and preoperative tumor reduction:
- Superselective Renal Artery Embolization: Through a femoral puncture, a microcatheter navigates to the segmental renal arteries feeding the tumor. Embolic agents are delivered to permanently block the tumor's blood supply. The tumor shrinks rapidly, bleeding stops, and the patient stabilizes. This converts an emergency into a planned elective surgery—or, for palliative cases, controls the disease without surgery.
- Pre-Operative Tumor Downstaging: For large tumors with renal vein tumor thrombus or bulky local disease, embolization shrinks the tumor by 30–50% within weeks—making subsequent partial or radical nephrectomy safer, with less blood loss and shorter operative time.
- Palliative Hemorrhage Control: For metastatic or inoperable patients with recurrent hematuria, repeated targeted embolization can control bleeding episodes and reduce transfusion dependence—improving quality of life.
What this means for you: When the tumor is too large or the bleeding too severe for immediate surgery, our interventional team can starve the tumor and stop the hemorrhage—giving you the strength and stability to proceed with definitive treatment, or providing lasting comfort when surgery is not an option.
"The scan shows spots in my lungs and bones. They say the cancer has spread. Is there any point in continuing treatment?"
The challenge: Renal cell carcinoma frequently metastasizes to lung, bone, liver, and brain. The diagnosis of metastatic disease feels like a death sentence. Yet kidney cancer metastases are among the most responsive to modern targeted and local ablative therapies—if you have the right tools.
Our answer: A multi-modal metastasis-directed platform:
- CyberKnife M6 for Oligometastases: For 1–5 lung, bone, or liver metastases, 0.1mm sub-millimeter stereotactic radiosurgery tracks tumor motion and converges radiation from thousands of angles. It ablates metastases without a single incision—while you remain on systemic therapy uninterrupted. For bone lesions, this prevents pathological fracture and controls pain.
- Image-Guided Ablation: For small lung or bone metastases, RFA, MWA, or cryoablation destroys the lesion through a needle puncture—no open surgery, no interruption to targeted therapy.
- Iodine-125 Seed Implantation: For painful vertebral or pelvic bone metastases, rice-grain-sized radioactive seeds are implanted directly into the bone—delivering continuous local radiation for pain control and fracture prevention.
- Tumor Hyperthermia: For painful bone metastases receiving palliative radiation, regional hyperthermia to 40–43°C sensitizes cancer cells to radiation—amplifying pain relief and local tumor destruction without increasing toxicity.
What this means for you: Metastatic kidney cancer is not a terminal diagnosis—it is a chronic condition to be managed aggressively. We can ablate your lung spots, radiate your bone lesions, and seed your painful metastases—all while systemic therapy keeps the disease controlled systemically.
"I have been on sunitinib or pazopanib, and now the cancer is growing again. What comes next? And can I afford to keep fighting?"
The challenge: Metastatic renal cell carcinoma requires sequential lines of targeted therapy. Resistance to first-generation TKIs (sunitinib, pazopanib) is inevitable. When standard VEGF-targeted agents fail, patients in many regions face limited options and prohibitive costs for next-generation drugs.
Our answer: In China, the next line is mapped to your tumor's biology—and it is accessible at a fraction of the cost:
- Second-Line TKIs: Axitinib, cabozantinib, and lenvatinib are approved and in routine use for progression after first-line therapy—targeting VEGFR, MET, and AXL with greater potency.
- mTOR Inhibitors: Everolimus and temsirolimus provide a distinct mechanistic pathway for TKI-resistant disease.
- Immunotherapy Combinations: Nivolumab (anti-PD-1) plus ipilimumab (anti-CTLA-4) and pembrolizumab plus axitinib are approved first-line and salvage regimens in China—delivering durable responses by unleashing the immune system against kidney cancer.
- China-Original Protocols & Cost: Domestic PD-1 inhibitors combined with TKIs are in routine use, often years ahead of availability elsewhere. Comprehensive treatment costs are 30%–50% of what you would pay in Europe or the US—with zero compromise in quality.
- Phase III Clinical Trial Fast-Track: When approved drugs fail, rapid access to trials of next-generation HIF-2α inhibitors (belzutifan), novel bispecific antibodies, and combination immunotherapy—typically 3–5 years ahead of availability elsewhere.
Guided by NGS-based molecular profiling and physicians who have sequenced thousands of RCC cases through multiple lines.
What this means for you: TKI resistance is a milestone, not a wall. Your tumor's VEGFR, mTOR, or PD-L1 profile opens a direct path to the next effective drug—available here, sequenced by experienced physicians, at a sustainable cost.
When standard therapies reach their limit, we provide rapid access to China's full portfolio of Phase III clinical trials—therapies typically 3–5 years ahead of availability elsewhere. NGS-based molecular matching identifies trials targeting your specific mutation. Every enrollment is ethics-approved with full medical supervision.
Our TCM program runs alongside your primary treatment as a "renal function and vitality optimizer":
Toxicity Reduction: Herbal formulations help protect residual kidney function, ease TKI-induced hand-foot syndrome and hypertension, reduce fatigue, and manage immune-related side effects from PD-1 therapy.
Efficacy Enhancement: Selected preparations may improve tumor sensitivity to targeted or immunotherapy agents.
Acupuncture provides additional support for fatigue, pain, and treatment-related anxiety. The goal: protect your remaining kidney capacity, reduce treatment burden, and keep you strong enough to complete every planned cycle.
Every kidney cancer case is reviewed by a panel comprising urologic oncology surgery, interventional radiology, medical oncology, radiation oncology, radiology, pathology, and nephrology specialists. Kidney cancer decisions are uniquely complex: partial nephrectomy versus ablation versus active surveillance; embolization timing for large tumors; sequencing of TKIs, mTOR inhibitors, and immunotherapy through lines of resistance; and management of paraneoplastic syndromes.
The MDT convenes within 48 hours of complete documentation. Your plan is a consensus decision optimized for your tumor stage, molecular profile, renal function, comorbidities, and your priorities.
Ms. Yu, 50 years old, was diagnosed with right renal cell carcinoma in 2019 and underwent resection. Subsequently, she had five additional surgeries at multiple top-tier hospitals in Beijing, Henan, Anhui, and other locations. Despite multiple surgeries, Ms. Yu's condition still failed to be effectively controlled and even showed signs of deterioration.
- September 2019: Underwent right renal cell carcinoma resection. Pathological stage: pT3aNxMO.
- November 2019: Metastasis found in the left upper lung; underwent left upper lobectomy.
- April 2020: Head MRI indicated multiple space-occupying lesions in the left lateral ventricle trigone and right cerebellar hemisphere; underwent brain metastasis resection (details unspecified).
Thus, Ms. Yu made the arduous journey to Foshan. To better tailor the treatment plan, a comprehensive examination was performed. The results revealed an urgent situation with brain metastases: multiple abnormal signal shadows in the cerebellar vermis, left posterior horn of the lateral ventricle, and surrounding white matter, considered likely multiple metastases with possible hemorrhage; abnormal signal shadow in the right cerebellar hemisphere, considered a possible metastasis; post-operative changes in the neck consistent with metastatic tumor resection, and possible bilateral cervical metastatic lymphadenopathy.
After taking the medication for a period, the results were unexpected. Ms. Yu's physical condition improved rapidly. Within just two weeks, she recovered from a semi-comatose state to clear consciousness, and her mobility gradually returned.
Once Ms. Yu's condition stabilized, Director Lu and Dr. Yang personally designed her radiotherapy plan.
In January 2021, using Linear Accelerator-based SBRT technology, precise radiotherapy was delivered to the metastatic tumors in Ms. Yu's right cerebellum/corpus callosum splenium left side.
Just as everything was moving in a positive direction, A PET/CT examination revealed a breast mass in Ms. Yu, diagnosed as newly occurring breast cancer.
- January 2021: Underwent ultrasound-guided minimally invasive vacuum-assisted biopsy for the left breast mass. Post-operative pathological diagnosis was left breast ductal carcinoma in situ (intermediate grade). Received post-operative adjuvant radiotherapy combined with endocrine therapy.
- June 2022: PET/CT indicated that while the brain metastases were significantly regressing, the left breast lesion area still showed high metabolic activity.
- October 2022: Ms. Yu's breast mass symptoms became apparent. A puncture biopsy was performed, with a preliminary diagnosis of: invasive breast cancer.
- November 2022: Underwent modified radical mastectomy for left breast cancer. The tumor size was approximately 2cm x 1cm x 0.8cm. Pathology confirmed left breast invasive ductal carcinoma (IDC, rpT2N0M0, HER-2 overexpressing type). After multidisciplinary discussion, she received 6 cycles of TPH maintenance chemotherapy regimen.
- February 2023: Underwent resection of the left chest wall lesion. The procedure was smooth.
By March 2023, Ms. Yu's breast condition had significantly improved following treatment. Subsequently, she underwent radiotherapy for the tumor lesion near the medial aspect of the right ascending colon, using CyberKnife SBRT. The procedure was smooth.
In July 2023, a full-body PET/CT examination revealed that the tumors throughout Ms. Yu's body had completely disappeared, achieving a state of clinical complete remission on PET/CT. Ms. Yu returned for follow-up examinations twice. Her energy and spirit had recovered remarkably well.
Led by Dr. Yang Jun, Prof. Luo Pengfei, and Prof. Chen Tao, the Fosun Oncology Center brings together more than 20 world-class medical experts, each with over a decade of extensive oncology experience. Supported by a comprehensive range of advanced therapies — including robotic surgery, precision radiotherapy, minimally invasive intervention, CAR-T cell therapy, and Tumor Treating Fields (TTFields) — the center delivers one-stop, integrated cancer care designed to make treatment more accessible, efficient, and high-quality for every patient.
Key Highlights
- Over 60,000 annual oncology patient admissions across Fosun’s major international hospitals in 2025
More than 17,000 cumulative TACE procedures completed between 2023 and 2025 at Fosun Hospital Guangzhou alone, with international patients accounting for over 10% of total cases
- More than 1,000 successful CyberKnife treatments performed, demonstrating world-class expertise in precision radiotherapy
- A 29.3% five-year survival rate achieved for Glioblastoma Multiforme (GBM) through combined TTFields therapy, representing a significant improvement over the 4.7% baseline
Core Services
- Robotic surgery
- Precision radiotherapy
- Minimally invasive intervention
- CAR-T cell therapy
- Tumor Treating Fields (TTFields)
- Medical oncology
- PET/CT imaging
- Pulmonary nodule diagnosis
- VIP inpatient wards
- Integrated oncology clinics
- Traditional Chinese medicine for oncology
- Cancer screening and early detection
- Genetic testing and counseling
Founded in 1992, Fosun has grown over the past three decades into a global innovation-driven consumer group. In 2007, Fosun International Limited was listed on the Main Board of the Hong Kong Stock Exchange (stock code: 00656.HK). As one of the few Chinese enterprises with strong global operational and investment capabilities, Fosun has developed substantial technological expertise and innovation capacity across multiple industries.
Established in 2010, Shanghai Fosun Health Technology is dedicated to building a world-renowned healthcare group in Asia. Today, the group operates 19 affiliated medical institutions across Foshan, Guangzhou, Shenzhen, Zhuhai, Shanghai, and other major cities, with a total of 6,600 hospital beds and 9 Internet Hospital licenses. Fosun Health ranks No. 1 among China’s private comprehensive medical groups. Its flagship institution, Fosun Foshan Chancheng Hospital, has ranked first among private hospitals in China for eight consecutive years and was honored with the 2026 Global Health Asia-Pacific “Oncological Medical Service Provider of the Year” award.
As the flagship hospital of Fosun Health, Fosun Foshan Chancheng Hospital was founded in 1958. The hospital currently hosts 28 key specialty development programs, including 2 provincial-level, 13 municipal-level, and 13 district-level key specialties. Its services span 22 medical disciplines, including spinal orthopedics, traditional Chinese medicine gynecology, obstetrics and gynecology, cardiovascular medicine, clinical laboratory medicine, anesthesiology, pediatrics, critical care medicine, ultrasound medicine, rehabilitation medicine, general practice, general surgery, and urology.
The hospital is equipped with globally advanced medical technologies, including the CyberKnife system and the Da Vinci Surgical Robot. It has 1,750 approved hospital beds and a multidisciplinary team of more than 2,800 medical professionals. The hospital records nearly 3.19 million outpatient visits annually and more than 67,000 inpatient discharges each year.
Fosun Foshan Chancheng Hospital has received numerous prestigious recognitions, including:
Global Health Asia-Pacific “Traditional Chinese Medicine Hospital of the Year”
Global Health China “Hospital of the Year”
No. 1 ranking on the GAHA Top 500 Private Hospitals in China list for eight consecutive years
The hospital has also been recognized as:
A National Model Unit for Improved Medical Services
A National Drug Clinical Trial Institution (GCP)
A National Standardized Residency Training Base
Established in 2003, Guangzhou Fosun Chancheng Hospital specializes in cardiovascular medicine, oncology, and neurosciences. The hospital has established a National Chest Pain Center, Stroke Center, Trauma Center, and MDT Center, supporting the development of emergency medicine, obstetrics and gynecology, intensive care, anesthesiology, gastroenterology, general surgery, urology, and general practice.
The hospital operates more than 800 inpatient beds and 48 clinical and medical technology departments, supported by a team of over 880 healthcare professionals.
Guangzhou Fosun Chancheng Hospital has received several honors and industry recognitions, including:
EMBA Innovation Practice Base
Guangdong Private Medical Reform & Innovation Brand
Guangdong Private Medical Industry Pioneer Brand
Outstanding Brand Hospital for Medical Investment Contribution
Upload your abdominal CT/MRI images, renal biopsy pathology report, chest CT, PET-CT, and NGS results (VHL, PBRM1, MET, PD-L1). Our multidisciplinary kidney cancer team will provide a personalized treatment plan—including kidney preservation assessment and neoadjuvant downstaging strategy—within 48 hours.
